Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. PT Darya-Varia Laboratoria Tbk's Revenue for the
three
months ended in Jun. 2026 was Rp613,799 Mil. PT Darya-Varia Laboratoria Tbk's average Accounts Receivable for the
three
months ended in Jun. 2026 was Rp825,999 Mil.
Hence, PT Darya-Varia Laboratoria Tbk's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.74.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
PT Darya-Varia Laboratoria Tbk Receivables Turnover Related Terms
PT Darya-Varia Laboratoria Tbk Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:DVLA vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Darya-Varia Laboratoria Tbk's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Darya-Varia Laboratoria Tbk Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Darya-Varia Laboratoria Tbk's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where PT Darya-Varia Laboratoria Tbk's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a Receivables Turnover of 0.74 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. According to the industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #780 out of 948 companies in the Drug Manufacturers industry, placing it in the top 82.3%.
Is PT Darya-Varia Laboratoria Tbk's Receivables Turnover too high?
PT Darya-Varia Laboratoria Tbk's current Receivables Turnover is 0.74. The Drug Manufacturers industry median Receivables Turnover is 5.07. PT Darya-Varia Laboratoria Tbk's value of 0.74 is 85.4% below this industry median. Based on the distribution chart, PT Darya-Varia Laboratoria Tbk ranks #780 out of 948 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Darya-Varia Laboratoria Tbk's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #780 out of 948 companies for Receivables Turnover. This places PT Darya-Varia Laboratoria Tbk in the lower half of its industry. The industry median Receivables Turnover is 5.07. PT Darya-Varia Laboratoria Tbk's value of 0.74 is 85.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Darya-Varia Laboratoria Tbk's current Receivables Turnover of 0.74 is 85.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Darya-Varia Laboratoria Tbk's current Receivables Turnover is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,861.38, compared to a current price of Rp1,585.00 — trading 14.8% below its estimated fair value. The current Receivables Turnover is 0.74 and 85.4% below the Drug Manufacturers industry median of 5.07. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current Receivables Turnover is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued.
The current stock price of Rp1,585.00 is trading 14.8% below its estimated GF Value™ of Rp1,861.38.
GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.
Key valuation signals for ISX:DVLA:
Receivables Turnover: 0.74
GF Value™: Rp1,861.38 vs. price of Rp1,585.00 (14.8% below fair value)
Industry Position: 85.4% below the Drug Manufacturers median (#780 of 948)
No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.
74GF Score
Get the complete analysis for ISX:DVLA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DVLA has been successfully added to your 
